Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 7/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 10/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127337 | 0.82 | HTR3A (0.49) | OGAPANK3 | |
| SCHEMBL13466366 | 0.82 | CNR2 (0.48) | OGAPANK3ACACB | |
| SCHEMBL14349207 | 0.82 | PANK3 (0.46) | OGAPANK3SMOACACB | |
| SCHEMBL14924078 | 0.81 | OGA (0.50) | OGAPANK3ACACB | |
| SCHEMBL4547927 | 0.80 | CNR2 (0.50) | OGAPANK3 | |
| SCHEMBL24827960 | 0.79 | OGA (0.40) | OGAPANK3 | |
| SCHEMBL24721124 | 0.79 | PANK3 (0.54) | PANK3SMOACACB | |
| SCHEMBL22873330 | 0.78 | PANK3 (0.43) | OGAPANK3SMO | |
| SCHEMBL22792013 | 0.78 | KMT2A (0.54) | PANK3SMO | |
| SCHEMBL14349220 | 0.78 | KDM4E (0.52) | OGAPANK3SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | OGA 2474/4885PANK3 2245/4885SMO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.